The long-term goal is to determine the genetic mechanism of expression of Hemopoietic histocompatibility (Hh) antigens on the surface of leukemic and normal progenitor cells and characterize the Hh molecules themselves. To that end the following Aims are described: 1. Confirm the conclusion that Hh antigenic expression on lymphoma cells is """"""""down-regulated"""""""" by trans-acting regulatory genes. Using both in vivo and in vitro assays for hybrid resistance in which """"""""cold target cells competition"""""""" can be measured, we observed that ACCb H-2d/H-2b loss mutants which had lost Dd gained the expression of Hhb. 2. Map the Hh genes more precisely. B10.RQDB is a new H-2 recombinant described by Chella David, which expresses Dd, Db, but not Ld. Therefore, recombination occurred between D and L and Db is really Lb. The marrow cells have lost Hhb, retained Hhd for allogenic hosts and have decreased Hhd for F1 hybrid hosts. There and other new recombinants will be used to map Hh, which should be contromeric to L since the sequence is D (R) L in the D-region. (3) Test the cis gene hypothesis, i.e. an adjacent gene regulates Hh expression. Use same new H-2 recombination to detect gene(s) between S and L which may regulate Hh expression in heterozygotes that regulated """"""""tolerance"""""""" to parental Hh antigen. (4) Continue to test the """"""""allogenic inhibition"""""""" hypothesis for hybrid resistance. Marrow cells from C.B-17 scid/scid donors, which cannot generate alloreactive T or B cells, nevertheless are rejected by irradiated allogeneic or F1 hybrid recipient mice. (5) Characterize Hh molecules. 2-D gels of lysates of 35S-methionine labeled EL-4 and various ACCb cell lines, followed by computer analysis of radiographs, identified a 90 kd molecule as a potential candidate for the Hhb antigen. We will generate antibodies to isolate the molecules, and study its structure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036921-09
Application #
3174580
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1984-03-01
Project End
1995-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
George, T C; Mason, L H; Ortaldo, J R et al. (1999) Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. J Immunol 162:2035-43
George, T C; Ortaldo, J R; Lemieux, S et al. (1999) Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J Immunol 163:1859-67
Kumar, V; George, T; Yu, Y Y et al. (1997) Role of murine NK cells and their receptors in hybrid resistance. Curr Opin Immunol 9:52-6
Liu, J; Sentman, C L; Kumar, V et al. (1997) Murine marrow coexpressing H2-Dsp2 and H2-Db on host natural killer cell rejection. Transplantation 63:444-9
Manoussaka, M; Georgiou, A; Rossiter, B et al. (1997) Phenotypic and functional characterization of long-lived NK cell lines of different maturational status obtained from mouse fetal liver. J Immunol 158:112-9
George, T; Yu, Y Y; Liu, J et al. (1997) Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts. Immunol Rev 155:29-40
Moore, T A; Bennett, M; Kumar, V (1996) Murine natural killer cell differentiation: past, present, and future. Immunol Res 15:151-62
Yu, Y Y; George, T; Dorfman, J R et al. (1996) The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 4:67-76
Liu, J; Yu, Y Y; Lindahl, K F et al. (1996) Allorecognition by murine natural killer cells: studies with bone marrow transplants and lysis of T lymphoblasts. Chem Immunol 64:164-80
Stoneman, E R; Bennett, M; An, J et al. (1995) Cloning and characterization of 5E6(Ly-49C), a receptor molecule expressed on a subset of murine natural killer cells. J Exp Med 182:305-13

Showing the most recent 10 out of 44 publications